Related Experiment Video
Updated: Nov 23, 2025
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases
César Sánchez1, Francisco Domínguez2, Héctor Galindo1
1Departamento de Hematología-Oncología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Background:
About 80% of breast cancer (BC) cases express estrogen receptor (ER), which has been correlated with good prognosis and response to estrogen deprivation Aim: To characterize ER positive advanced BC (ABC) patients treated at our institution assessing the impact of clinical pre-sentation (stage IV, de novo disease at diagnosis versus systemic recurrence) and BC subtype on survival rates.
Material And Methods:
We evaluated 211 ER+ advanced BC (ABC) patients, treated between 1997 and 2017.
Results:
The median overall survival (OS) was 37 months. Median OS for the period 1997/2006 and 2007/2017 were 33 and 42 months, respectively (p = 0.47). Luminal A, ABC stage IV disease at diagnosis displayed better OS rates than Luminal B stage IV tumors (100 and 32 months respectively, p < 0.01).
Conclusions:
Clinical presentation (stage IV vs. systemic recurrence) and tumor subtype are key determinants of OS in ABC.
More Related Videos
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
01:21Cancer Survival Analysis
01:20Comparing the Survival Analysis of Two or More Groups
01:20Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...